Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetate + butyrate + propionate
- Development stage
- Preclinical
- Lead developer
- NHS R&D Regional Programme Register - Department of Health (UK)
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal, Intravenous
01
Overview
A combination of acetate, butyrate, and propionate refers to a mixture of the three primary short-chain fatty acids (SCFAs) produced by gut microbiota during the fermentation of dietary fibers. These SCFAs act as signaling molecules with multiple physiological effects. They are involved in energy metabolism (acetate is an energy source for host cells; propionate is used for gluconeogenesis), regulation of glucose uptake in muscle cells, modulation of inflammation via G-protein coupled receptors (GPR41/FFAR3 and GPR43/FFAR2), and inhibition of histone deacetylases (HDACs). The combination has been shown experimentally to increase glucose uptake in skeletal muscle cell models at certain concentrations and may contribute to improved metabolic health and anti-inflammatory effects. This combination is not a pharmaceutical drug per se but may be used as a dietary supplement or research tool[1][2][5][6][8].
- Brand names
- Prulab
- Other names
- acetatebutyratepropionateshort-chain fatty acids mixtureSCFA mixture
02
Targets
FFAR2HDAC (HDAC family)FFAR3 (Free fatty acid receptor 3)
Beyond the preview
Go deeper on acetate + butyrate + propionate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetate + butyrate + propionate.